1. New European Anticoagulant Approvals Will They Affect Practical Guidance?

3. NOACs Key Factors for Acceptance Into General Practice

4. Edoxaban Newest NOAC Entry to the European Market

5. Edoxaban (cont) Newest NOAC Entry to the European Market

6. Edoxaban (cont) Newest NOAC Entry to the European Market

7. NOACs Renal Clearance

8. Approved European Labeling for NOACs and Dosing for CKD

9. Drug-Drug Interactions of NOACs

10. NOACs and Antivirals

11. Efficacy vs Safety Meta-analysis of 4 Pivotal Trials of NOACS

12. The Percentage of Strokes Attributable to AF Increases With Age

13. The Percentage of Strokes Attributable to AF Increases With Age

14. RE-VERSE AD: Multicenter, Ongoing, Phase 3 Study of Idarucizumab A Specific Reversal Agent for of Dabigatran

15. Andexanet Alpha (Recombinant, Modified Human Factor Xa)

16. PER977 (Di-arginine Piperazine)

17. To Switch or Not to Switch

18. Summary

19. Abbreviations

20. References

21. References (cont)